Chinese Journal of Practical Pediatrics ›› 2021, Vol. 36 ›› Issue (11): 839-842.DOI: 10.19538/j.ek2021110608

Previous Articles     Next Articles

Advances of slow- acting antirheumatic drug for juvenile dermatomyositis

  

  1. *Department of General Medicine(Immunology),Tianjin Children’ s Hospital(Children’s Hospital of Tianjin University),Tianjin  300074,China
  • Online:2021-11-06 Published:2022-01-04

幼年皮肌炎慢作用药物治疗进展

  

  1. 1.天津市儿童医院(天津大学儿童医院)综合内科(免疫),天津  300074;2. 天津医科大学研究生院,天津  300070
  • 通讯作者: 胡坚,电子信箱:h1957_7591@126.com

Abstract: Juvenile dermatomyositis is one of the rare rheumatic diseases in children. The common treatment is hormone combined with slow-acting drugs. It is difficult to choose slow-acting drugs,swith drugs and design course of treatment because of the low incidence and lack of large randomized controlled trials. The author summarizes the common slow-acting antirheumatic drugs used in the treatment of juvenile dermatomyositis,and introduces the mechanism of action,dosage,adverse reactions and indications of these drugs,in order to help doctors to select drugs.

Key words: juvenile dermatomyositis, slow- acting antirheumatic drug, treatment

摘要: 幼年皮肌炎是儿童少见的风湿性疾病之一,常用的治疗方案是激素联合慢作用药物。由于发病率较低,缺少大样本随机对照试验研究,选择哪种慢作用药物、了解药物之间的转换以及确定疗程是比较困难的。该文对治疗幼年皮肌炎的常用慢作用药物及其作用机制、剂量、不良反应和适应证进行介绍,有助于临床医师对药物选择进行权衡。

关键词: 幼年皮肌炎, 慢作用抗风湿药物, 治疗